Preliminary Phase 1 trial data show that uTREAT, Curasight’s experimental targeted cancer therapy, was safely delivered to aggressive solid brain tumors and reached estimated…
News
SIM0505, a treatment being developed by Nextcure and Simcere Zaiming, resulted in partial responses in more than half of patients with hard- to-treat…
The European Commission has approved a new subcutaneous (under-the-skin) formulation of Sarclisa (isatuximab), a treatment for multiple myeloma that was previously available in…
The U.S. Food and Drug Administration (FDA) has approved a new formulation of the anticancer therapy nilotinib, branded Cavhanza, to treat certain people with chronic…
Ideaya Biosciences and Roche announced a collaboration to test two experimental treatments for pancreatic cancer in combination. The companies will test Ideaya’s…
Add-on treatment with DeltEx DRI, a cell therapy being developed by In8bio, may help prolong survival in people with glioblastoma, an aggressive form of…
A combination of the immune-modulating treatments Lymphir (denileukin diftitox) and Keytruda (pembrolizumab) led to clinical benefit in nearly half of evaluable patients in an exploratory clinical…
Treatment with a regimen based on the experimental therapy mezigdomide reduced the risk of disease progression or death by more than 50% compared with standard…
The U.S. Food and Drug Administration (FDA) has granted fast-track designation to STX-0712, an experimental therapy Solu Therapeutics is developing to treat chronic myelomonocytic…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to an experimental delivery method for the chemotherapy oxaliplatin as a potential treatment…
